Literature DB >> 12373581

Contraception and pregnancy in women affected by glycogen storage diseases.

Valérie Mairovitz1, Philippe Labrune, Hervé Fernandez, Francois Audibert, René Frydman.   

Abstract

UNLABELLED: During the last decades, better understanding of specific enzymatic deficiencies has led to improved dietary management of children suffering from glycogen storage disease (GSD). Normal growth and development of infants can be achieved by a diet of regular meals supplemented by glucose and cornstarch during the night, and by monitoring glucose blood levels. This has resulted in an increase in the number of patients reaching adulthood and reproduction age. Therefore, developing a strategy for an optimal management of contraception and pregnancy is crucial for young women affected by GSD. Contraception has to be adapted to the specific metabolic requirements of women with GSD. Hormonal contraception is classically based on the combination of various synthetic progestogens and ethinyloestradiol. Ethinyloestradiol should be avoided because of a link with hepatic adenomas and is contraindicated in patients with hypertriglyceridaemia and hypercholesterolaemia. Blockade of ovulation can be achieved using high doses of progestogen alone, administered from the 5th to the 25th day of the cycle. Another scheme of hormonal contraception is based on daily administration of low doses of progestogen, which usually acts on local parameters of fertility, and can also achieve blockade of ovulation for the most recent compound proposed. Mechanical contraception using intra-uterine device is controversial for nulliparous patients. Benefits and side-effects of these different proposals are discussed. During pregnancy, the maternal nutritional state is important and a healthy maternal response to feeding and fasting is modified to ensure a constant supply of glucose for the developing fetus. Women with GSD are at risk of frequent hypoglycaemia. Only a few cases of successful pregnancies have been reported for patients with GSD. The outcomes using different approaches of dietary and obstetric management are discussed.
CONCLUSION: in the future, multidisciplinary management is necessary to improve obstetric outcome of pregnancy in females affected with glycogen storage disease.

Entities:  

Mesh:

Year:  2002        PMID: 12373581     DOI: 10.1007/s00431-002-1013-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  5 in total

1.  Perioperative management of hemostasis for surgery of benign hepatic adenomas in patients with glycogen storage disease type ia.

Authors:  Alix Mollet-Boudjemline; Aurélie Hubert-Buron; Catherine Boyer-Neumann; Roxana Aldea; Dominique Franco; Pascale Trioche-Eberschweiller; Anne-Elisabeth Mas; Mylène Mabille; Philippe Labrune; Vincent Gajdos
Journal:  JIMD Rep       Date:  2011-06-22

2.  Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study.

Authors:  Annalisa Sechi; Laura Deroma; Annunziata Lapolla; Sabrina Paci; Daniela Melis; Alberto Burlina; Francesca Carubbi; Miriam Rigoldi; Maja Di Rocco
Journal:  J Inherit Metab Dis       Date:  2012-05-05       Impact factor: 4.982

3.  Pregnancies in glycogen storage disease type Ia.

Authors:  Daniëlle H J Martens; Jan Peter Rake; Martin Schwarz; Kurt Ullrich; David A Weinstein; Martin Merkel; Pieter J J Sauer; G Peter A Smit
Journal:  Am J Obstet Gynecol       Date:  2008-02-01       Impact factor: 8.661

Review 4.  Glucose-6-phosphatase deficiency.

Authors:  Roseline Froissart; Monique Piraud; Alix Mollet Boudjemline; Christine Vianey-Saban; François Petit; Aurélie Hubert-Buron; Pascale Trioche Eberschweiler; Vincent Gajdos; Philippe Labrune
Journal:  Orphanet J Rare Dis       Date:  2011-05-20       Impact factor: 4.123

Review 5.  Contraceptive use in women with inherited metabolic disorders: a retrospective study and literature review.

Authors:  Jessica I Gold; Nina B Gold; Diva D DeLeon; Rebecca Ganetzky
Journal:  Orphanet J Rare Dis       Date:  2022-02-08       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.